Cargando…

Enrichment of novel Tau isoform with altered biochemical properties in Alzheimer’s disease

Detalles Bibliográficos
Autor principal:	Ong, Chin-Tong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360115/ https://www.ncbi.nlm.nih.gov/pubmed/37282466 http://dx.doi.org/10.4103/1673-5374.371359

Ejemplares similares

Truncated Tau caused by intron retention is enriched in Alzheimer’s disease cortex and exhibits altered biochemical properties
por: Ngian, Zhen-Kai, et al.
Publicado: (2022)

Increased intron retention is linked to Alzheimer’s disease
por: Ong, Chin-Tong, et al.
Publicado: (2019)

Extracellular vesicles drive tau spreading in Alzheimer's disease
por: Ruan, Zhi
Publicado: (2021)

Microtubule affinity regulating kinase (MARK/Par1) isoforms differentially regulate Alzheimer-like TAU missorting and Aβ-mediated synapse pathology
por: Chudobová, Jana, et al.
Publicado: (2022)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
por: Imbimbo, Bruno P., et al.
Publicado: (2022)

Neurofibrillary tangles in Alzheimer's disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics
por: Metaxas, Athanasios, et al.
Publicado: (2016)

Fluent molecular mixing of Tau isoforms in Alzheimer’s disease neurofibrillary tangles
por: Dregni, Aurelio J., et al.
Publicado: (2022)

Imaging tau pathology in Alzheimer’s disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies
por: Moscoso, Alexis, et al.
Publicado: (2022)

Novel pluripotent stem cell lines for enriched grafting in Parkinson’s disease
por: Cota-Coronado, Agustin, et al.
Publicado: (2019)

Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington’s Disease
por: Fernández-Nogales, Marta, et al.
Publicado: (2020)

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease
por: Bichmann, Maria, et al.
Publicado: (2021)

Lingo-1: a novel target in therapy for Alzheimer's disease?
por: Fernandez-Enright, Francesca, et al.
Publicado: (2016)

3R and 4R tau isoforms in paired helical filaments in Alzheimer’s disease
por: Hasegawa, Masato, et al.
Publicado: (2013)

A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer’s disease
por: García-Escudero, Vega, et al.
Publicado: (2021)

Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer’s disease
por: Cherry, Jonathan D., et al.
Publicado: (2021)

It takes more than tau to tangle: using proteomics to determine how phosphorylated tau mediates toxicity in neurodegenerative diseases
por: Pires, Geoffrey, et al.
Publicado: (2021)

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

A simple human cell model for TAU trafficking and tauopathy-related TAU pathology
por: Bell, Michael, et al.
Publicado: (2021)

Preventative medicine and Alzheimer’s disease: is Alzheimer’s disease risk reduction achievable?
por: Sinyor, Benjamin, et al.
Publicado: (2021)

Biochemical consequences of glucocerebrosidase 1 mutations in Parkinson’s disease
por: Yoon, Jeong Hyun, et al.
Publicado: (2023)

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society
por: Erickson, Claire M., et al.
Publicado: (2022)

Newfound physiological function of FAIM protein offers hope of novel disease-modifying therapy for Alzheimer’s disease
por: Balaj, Allison R., et al.
Publicado: (2023)

Acid-sensing ion channel 1a: a novel target in Alzheimer’s disease?
por: Mango, Dalila, et al.
Publicado: (2022)

N-methyl-D-aspartate receptor functions altered by neuronal PTP1B activation in Alzheimer’s disease and schizophrenia models
por: Stewart, Alexandre F. R., et al.
Publicado: (2022)

Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression
por: Chen, Hsu-Hsin, et al.
Publicado: (2018)

Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer’s disease
por: Yang, Yun, et al.
Publicado: (2022)

The Harvard method of Tau calculation is incorrect
por: Horning, Andrew, et al.
Publicado: (2019)

Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
por: Ketchum, Fred B., et al.
Publicado: (2022)

OxInflammation in Alzheimer’s disease
por: Cervellati, Carlo, et al.
Publicado: (2023)

Endocannabinoid metabolism and Alzheimer's disease
por: Chen, Chu
Publicado: (2022)

Small molecules to target tau amyloid aggregation
por: Manglano-Artuñedo, Zoe, et al.
Publicado: (2023)

Alzheimer’s Disease is a Disorder of Consciousness
por: Yokoi, Teruo
Publicado: (2023)

Open drug discovery in Alzheimer's disease
por: Axtman, Alison D., et al.
Publicado: (2023)

Reevaluating the cause of laminopathy in Alzheimer’s disease
por: Islam, Md Imamul, et al.
Publicado: (2023)

Next generation therapeutics for Alzheimer's disease
por: Bredesen, Dale E, et al.
Publicado: (2013)

New Approaches to Treating Alzheimer’s Disease
por: Zheng, Hailin, et al.
Publicado: (2015)

Advancing combination therapy for Alzheimer's disease
por: Salloway, Stephen P., et al.
Publicado: (2020)

The pathway to secondary prevention of Alzheimer's disease
por: McDade, Eric, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l3tekidsqp5g1q9ocb80qfua4h